Loading...
OTCM
SAUHY
Market cap16bUSD
Oct 08, Last price  
10.50USD
1D
-3.58%
1Q
-19.44%
Name

Straumann Holding AG

Chart & performance

D1W1MN
OTCM:SAUHY chart
P/E
38.87
P/S
5.34
EPS
2.25
Div yield, %
1.02%
Shrs. gr., 5y
0.07%
Rev. gr., 5y
12.82%
Revenues
2.61b
+4.09%
599,204,000713,654,000778,708,000736,361,000737,648,000693,581,000686,253,000679,922,000710,270,000798,600,000917,516,0001,112,102,0001,363,560,0001,596,225,0001,425,851,0002,021,903,0002,320,785,0002,411,819,0002,503,900,0002,606,248,863
Net income
358m
-7.76%
141,725,000175,866,0008,163,000146,373,000131,084,00070,952,00036,438,000101,201,000157,825,00070,679,000229,600,000272,917,000272,770,000306,473,00091,282,000396,079,000434,789,000246,072,000388,316,000358,171,628
CFO
506m
+4.61%
174,581,000223,153,000198,758,000245,142,000175,841,000140,216,000114,560,000151,490,000146,160,000185,598,000184,743,000217,290,000277,099,000378,478,000376,594,000560,303,000415,155,000503,950,000483,387,000505,657,301
Dividend
Apr 22, 20260.127 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Straumann Holding AG is a global leader in providing advanced solutions for tooth replacement and orthodontic treatment. The company actively researches, develops, manufactures, and distributes a comprehensive range of dental products and services designed for tooth correction, restoration, replacement, and the prevention of tooth loss. Its extensive portfolio includes various dental implant systems (such as titanium, titanium alloy, ceramic, and mini implants), specialized surgical instruments, sophisticated CAD/CAM prosthetics, and the Clear Correct orthodontic aligners. Straumann also supplies vital biomaterials, including bone substitutes, membranes, and biologics, alongside cutting-edge digital tools like intraoral scanners, 3D printers, and milling machines for dental professionals and laboratories. Additionally, the company offers educational and training services to its customers. Straumann serves a diverse clientele, encompassing general dentists, specialists, dental technicians, laboratories, and institutional clients such as distributors, hospitals, and universities, reaching approximately 100 countries through its broad network of subsidiaries and partners. Established in 1954, Straumann Holding AG is headquartered in Basel, Switzerland.

Related entities

Subsidiaries
Institut Straumann AG

Key people

Guillaume Daniellot
Chief Executive Officer, Member of the Executive Management Board · since 2020
Non-Executive Vice Chairman of the Board of Directors · since 2010
Frank Hemm
Member of the Management Board, Head Customer Solutions & Education · since 2013
Wolfgang Becker
Member of the Executive Management Board, Head Distributor and Emerging Markets EMEA
Jens Dexheimer
Executive Vice President Sales Western Europe, Member of the Management Board · since 2016
Member of the Executive Management Board, Head Sales Latin America, Chief Executive Officer of Neodent · since 2016
Member of the Executive Management Board, Head of North American Region · since 2020
Monique Bourquin
Non-Executive Director · since 2017
Ulrich Looser
Non-Executive Director · since 2010
Non-Executive Director · since 2010
Non-Executive Director · since 2017
IPO date
Jun 01, 1998
Employees
10,543
Domiciled in
CH
Incorporated in
CH
Headquarters & legal address
Peter Merian-Weg 12
Basel, BS 4002
CH
Other language
Straumann Holding Ltd
Other language
Straumann Holding SA

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT